Cimlanod

Short description: Chemical compound

Cimlanod

Legal status
Legal status|

* Investigational

Identifiers

IUPAC name

* N-Hydroxy-5-methylfuran-2-sulfonamide

CAS Number|

* 1620330-72-4

PubChem CID|

* 76685198

DrugBank|

* DB14983

UNII|

* 2US4FK1EPV

Chemical and physical data
Formula| C5H7NO4S
Molar mass| 177.17 g·mol−1
3D model (JSmol)|

* Interactive image

SMILES

* CC1=CC=C(O1)S(=O)(=O)NO

Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a precursor of nitroxyl.[1]

Cimlanod is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

## References

1. ↑ "BMS 986231". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800040055. Retrieved 2017-05-22. "Alternative Names: BMS-986231; CXL 1427; HNO Donor"
2. ↑ "CXL 1020". AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800030450. Retrieved 2017-05-22.
3. ↑ "Nitroxyl prodrug shows promise in acute heart failure". 22 May 2016. http://www.mdedge.com/ecardiologynews/article/109035/heart-failure/nitroxl-prodrug-shows-promise-acute-heart-failure.
4. ↑ Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Cimlanod. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Cimlanod&oldid=815298"
*[CID]: Compound ID